Public description: Human NSCLC cell lines were chronically treated with sotorasib, RMC-4998, or a combination of sotorasib and RMC-4550 to generate resistant models. The cells were then subjected to
KRASG12C GDP form in complex with Cpd3 Descriptor: GUANOSINE-5'-DIPHOSPHATE, Isoform 2B of GTPase KRas, MAGNESIUM ION, ... Authors: Mathieu, M, Steier, V. Deposit date: 2020-08-14 Release date: 2021-1
Route design and proof of concept synthesis was conducted on a synthetically challenging atropisomeric KRASG12C inhibitor to support clinical API manufacture. Improvements to the synthesis of a chiral
